跳到正文

依鲁替尼

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 1 条

  1. 2023

    AbbVie就Brukinsa对BeiGene提起专利诉讼

    提起诉讼

    AbbVie旗下Pharmacyclics部门在特拉华州联邦法院起诉BeiGene,指称BeiGene的Brukinsa侵犯了AbbVie的Imbruvica专利。AbbVie寻求侵权宣告及赔偿;BeiGene表示将积极应对这些指控。

    当事方说明的目的. AbbVie寻求侵权宣告及赔偿。

    品牌回应

    • 否认 — BeiGene

      BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.

    来源摘录

    • Through its complaint, filed the same day in federal court in Delaware, US, AbbVie is seeking a declaratory judgment of infringement, as well as damages.
    • AbbVie’s Pharmacyclics unit has filed a lawsuit against BeiGene, alleging that the biotech’s Brukinsa (zanubrutinib) infringes a patent on its own blood cancer drug Imbruvica (ibrutinib).
    • BeiGene said in a statement that it will “vigorously defend” against all allegations of patent infringement.